Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Half year trading update

4 Jul 2008 07:00

RNS Number : 3113Y
Cello Group plc
04 July 2008
 



4 July 2008

Cello Group plc

Trading update - six months to 30 June 2008

Cello Group plc ("CelloAIM: CLL), the research and consulting group, today provides the following trading update for the six months to 30 June 2008

The Group has continued to make good progress across both of its operating divisions during the first half of 2008, with healthy like-for-like operating income growth. The Group will therefore deliver headline first half profits in line with expectations.

Divisional Trading

Our research and consulting business has performed well in the first six months. Most notably, our healthcare and public sector practices (which comprise approx 33% of the operating income of the Group) have delivered encouraging levels of growth and have a healthy pipeline going into the second half. Our consumer research businesses have also made an excellent contribution with growth being aided by a number of significant new international client wins and new continuous research projects.

We have continued our organic, client led international growth plan with the establishment of an office in San Francisco and we plan to open shortly in Germany. We have also continued our investment in digital and online research initiatives. Notwithstanding this investment, the Group expects its underlying operating margins in this division to be maintained at previous full year levels.

Our response business, which was rebranded as Tangible Group at the start of the year, has also performed well in the first half. The business is traditionally second half weighted as a substantial number of our charity clients have marketing budgets with a significant second half bias. Revenue visibility from such clients is generally very good. The division also has a growing number of public sector clients with committed spend. Our financial services clients continue to migrate budget to the more accountable elements of marketing spend. The Group expects underlying operating margins in this division to be at least one percentage point higher than the comparable period in 2007.

Headcount

The overall headcount of the Group has risen by 3% in the first six months of the year to over 820 peopleWe have invested in our growing digital, data, and UK qualitative research businesses. In some other areas of the Group headcount has been reduced as a matter of due prudence given the general economic outlookAs part of our regular review of our fixed cost structure, we have reduced annualised salary costs by £1.0m at a cost of £0.5m during the first half

Debt and Earn Out Obligations

In line with the Group's prudent funding policy, we have maintained a relatively low level of net debt and future cash obligations under earn out commitments. We expect net debt at 30 June 2008 to be c.£15.0m, and well within our agreed banking facilities.

In April 2008, the Group settled £14.4m of earn out and deferred consideration payments to over 80 vendors and employees of businesses acquired in 2004 and also some deferred initial consideration in respect of an acquisition made in 2007. This was satisfied by the payment of £8.0m in cash or loan notes and the issue of 5.6m shares at 114.5p.

Following this substantial settlement, the Group estimates that its future earn out liabilities have almost halved since 31 December 2007 to around £15.0m. The Group estimates that these future earn out obligationspayable between 2009 and 2013, will be settled by a minimum of £5.8m payable in loan notes and up to £9.2m payable by the issue of new shares.

Full Year Outlook

As stated at the time of the Annual General Meeting on 20 May 2008, the board is mindful of the macro economic environment and its potential impact on our business. We have good revenue visibility for the next quarter and subject to further conversion of existing opportunities and market conditions, we remain cautiously optimistic for the full year. We continue to actively manage our cost base across the Group.

We plan to announce our interim results on Tuesday 17 September 2008 and will further update the market on the trading outlook for the full year at that time.

Enquiries: 

Cello Group plc

 020 7812 8460

Kevin Steeds, Executive Chairman

Mark Scott, Chief Executive Officer

Mark Bentley, Finance Director

 

 

Kaupthing Singer and Friedlander Capital Markets 

 020 3205 5005

Nicholas How

Marc Young

 

 

 

College Hill

 020 7457 2020

Adrian Duffield/Rozi Morris

Notes to Editors (www.cellogroup.co.uk)

Cello is a market research and consulting group that listed on AIM in November 2004. The Group's strategy is to create value for shareholders by building a portfolio of research and consulting businesses capable of advising blue chip clients globally.

Cello has annualised turnover in excess of £130moperating income of over £70m and employs over 820 professional staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXXDEDAPEFE
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.